These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 11125287)

  • 21. [Radiolabeled monoclonal antibodies as anti-tumor missiles, their diagnostic success and therapeutic potential].
    Mach JP; Pèlegrin A; Folli S; Buchegger F
    Bull Acad Natl Med; 1992 Jun; 176(6):879-89. PubMed ID: 1464034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update.
    Sharkey RM; Karacay H; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5577s-5585s. PubMed ID: 17875792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
    Reilly RM
    J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
    [No Abstract]   [Full Text] [Related]  

  • 26. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy.
    Goldenberg DM
    Semin Nucl Med; 1989 Oct; 19(4):332-9. PubMed ID: 2678484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
    Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
    Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
    Zhu H; Jain RK; Baxter LT
    J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.
    Goldenberg DM; Juweid M; Dunn RM; Sharkey RM
    J Nucl Med Technol; 1997 Mar; 25(1):18-23; quiz 34. PubMed ID: 9239599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibodies in the therapy of colon cancer.
    Welt S; Ritter G
    Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in bispecific biotherapeutics for the treatment of cancer.
    May C; Sapra P; Gerber HP
    Biochem Pharmacol; 2012 Nov; 84(9):1105-12. PubMed ID: 22858161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy with bispecific antibodies.
    Thielemans KM
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Application of tumor marker for immunotargeting therapy of cancer].
    Yamaguchi T; Takahashi T; Kitamura K; Otsuji E
    Nihon Rinsho; 1996 Jun; 54(6):1674-9. PubMed ID: 8691628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibody-based therapy.
    von Mehren M; Weiner LM
    Curr Opin Oncol; 1996 Nov; 8(6):493-8. PubMed ID: 8971469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
    Sharkey RM; Juweid M; Shevitz J; Behr T; Dunn R; Swayne LC; Wong GY; Blumenthal RD; Griffiths GL; Siegel JA
    Cancer Res; 1995 Dec; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).
    Peña Y; Perera A; Batista JF
    MEDICC Rev; 2014; 16(3-4):55-60. PubMed ID: 25208121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.